Plain-English translation of NCT02131753 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing cladribine, a chemotherapy medication given as injections under the skin, to treat hairy cell leukemia in patients who have not received cancer treatment before. Researchers will check how well the treatment works about 4 months after you receive it, and if your cancer doesn't respond completely, they'll offer you a second round of the same medication to see if that helps.
Hairy cell leukemia is a rare blood cancer, and doctors want to find the best way to treat it. This study aims to improve outcomes by testing whether giving patients a second cycle of this medication benefits those whose cancer doesn't fully respond to the first treatment.
You likely qualify if…
You likely don't qualify if…
You will receive cladribine as injections under your skin once a day for 5 consecutive days. About 4 months after your treatment, you'll have blood tests and a bone marrow exam to see how well the medication worked. If your cancer hasn't fully responded, your doctor may offer you another 5-day cycle of the same injections. You'll be monitored throughout to check for side effects and track how well the treatment is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Germany